About Us
Ondek was established in 2005 to develop and commercialise a novel drug and vaccine delivery platform based on the use of genetically modified Helicobacter pylori bacteria. We call this technology the Helicobacter pylori Platform Technology (HPPT), a revolutionary drug and vaccine delivery vehicle that has potential application across the spectrum of the pharmaceutical industry.
Led by Nobel Prize winner Dr. Barry Marshall, Ondek has a world renowned research team and network of international collaborators focused on developing the HPPT.
Dr Marshall is a co-discoverer of the Helicobacter Pylori organism and a co-recipient of the 2005 Nobel Prize for Medicine and Physiology as well as multiple other prestigious awards (including the 1995 Lasker Award and elected a Fellow of the Royal Society in 1999). He is one of the most esteemed and pre-eminent biomedical scientists in the world today.